Juno Therapeutics (JUNO) has been under a strong bear grip, hence the stock is down -26.46% when compared to the S&P 500 in the past 4 weeks. However, in the near-term, buying emerged at lower levels and the stock has outperformed the S&P 500 by 6.25% in the past 1 week. The stock has risen by 6.18% in the past week indicating that the buyers are active at lower levels, but the stock is down -23.99% in the past 4 weeks.
The stock has recorded a 20-day Moving Average of 2.36% and the 50-Day Moving Average is 18.82%. Juno Therapeutics Inc. has dropped 26.51% during the last 3-month period . Year-to-Date the stock performance stands at -29.66%.
Juno Therapeutics (NASDAQ:JUNO): stock turned positive on Friday. Though the stock opened at $29.91, the bulls momentum made the stock top out at $31.0535 level for the day. The stock recorded a low of $29.75 and closed the trading day at $30.93, in the green by 3.41%. The total traded volume for the day was 1,254,155. The stock had closed at $29.91 in the previous days trading.
Juno Therapeutics, Inc. (Juno) is a biopharmaceutical company. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells. Junos product candidates, JCAR015, JCAR017 and JCAR014, utilize CAR technology to target CD19, a protein expressed on the surface of various B cell leukemias and lymphomas. Junos other product candidates include JCAR018: CD22, JCAR023: L1CAM (CD171), JCAR020: MUC-16 / IL-12, ROR-1 and JTCR016: WT-1. JCAR015 is in Phase I open label clinical trial stage for patients with acute lymphoblastic leukemia (r/r ALL). JCAR017 is in Phase I/II trial for patients with pediatric r/r ALL. JCAR014 is in Phase I/II trial as a treatment for various B cell malignancies in patients. JTRC016 is in Phase I/II clinical trial for the treatment of AML, myelodysplasic syndrome and chronic myeloid leukemia.